The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 09, 2020
Filed:
Jul. 18, 2014
Applicant:
Baylor College of Medicine, Houston, TX (US);
Inventors:
David J. Tweardy, Houston, TX (US);
Moses M. Kasembeli, Houston, TX (US);
Marvin X. Xu, Shanghai, CN;
Thomas Kristian Eckols, Houston, TX (US);
Assignee:
Baylor College of Medicine, Houston, TX (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 333/34 (2006.01); A61K 31/47 (2006.01); A61K 31/44 (2006.01); A61K 31/194 (2006.01); C07C 311/21 (2006.01); C07D 215/36 (2006.01); A61K 31/4406 (2006.01); A61K 31/415 (2006.01); A61K 31/381 (2006.01); A61K 31/357 (2006.01); A61K 31/145 (2006.01); C07D 213/71 (2006.01); C07D 231/18 (2006.01); C07D 319/18 (2006.01); C07C 311/08 (2006.01); C07C 311/10 (2006.01); C07C 311/13 (2006.01); C07C 311/24 (2006.01); C07C 311/29 (2006.01); C07C 311/44 (2006.01); C07C 323/49 (2006.01); C07C 381/06 (2006.01); A61K 45/06 (2006.01); A61K 31/18 (2006.01); A61K 31/4035 (2006.01); A61K 31/404 (2006.01); A61K 31/4164 (2006.01); A61K 31/4196 (2006.01); A61K 31/42 (2006.01); A61K 31/428 (2006.01); A61K 31/45 (2006.01); A61K 31/454 (2006.01); A61K 31/4704 (2006.01); A61K 31/4709 (2006.01); A61K 31/513 (2006.01);
U.S. Cl.
CPC ...
C07D 333/34 (2013.01); A61K 31/145 (2013.01); A61K 31/18 (2013.01); A61K 31/357 (2013.01); A61K 31/381 (2013.01); A61K 31/404 (2013.01); A61K 31/4035 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/4196 (2013.01); A61K 31/42 (2013.01); A61K 31/428 (2013.01); A61K 31/4406 (2013.01); A61K 31/45 (2013.01); A61K 31/454 (2013.01); A61K 31/47 (2013.01); A61K 31/4704 (2013.01); A61K 31/4709 (2013.01); A61K 31/513 (2013.01); A61K 45/06 (2013.01); C07C 311/08 (2013.01); C07C 311/10 (2013.01); C07C 311/13 (2013.01); C07C 311/21 (2013.01); C07C 311/24 (2013.01); C07C 311/29 (2013.01); C07C 311/44 (2013.01); C07C 323/49 (2013.01); C07C 381/06 (2013.01); C07D 213/71 (2013.01); C07D 215/36 (2013.01); C07D 231/18 (2013.01); C07D 319/18 (2013.01); C07C 2101/14 (2013.01); C07C 2102/10 (2013.01); C07C 2601/14 (2017.05); C07C 2602/10 (2017.05); Y02A 50/409 (2018.01);
Abstract
Embodiments of the invention include methods of treating, preventing, and/or reduce the risk or severity of a condition selected from the group consisting of muscle wasting, muscle weakness, cachexia, and a combination thereof in an individual in need thereof. In some embodiments, particular small molecules are employed for treatment, prevention, and/or reduction in the risk of muscle wasting. In at least particular cases, the small molecules are inhibitors of STAT3.